Relief Therapeutics Holding SA (OTCMKTS:RLFTF) : Subsidiary Gets Notice of Allowance of Key U.S. Patent Application Including PKU GOLIKE(R)
Biopharmaceutical company, Relief Therapeutics Holding SA (OTCMKTS:RLFTF) (striving to provide patients therapeutic relief from serious diseases with high unmet need), has made an announcement that its wholly owned subsidiary, APR Applied Pharma Research, has officially received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for Patent Application No. 15/303,121 entitled, “Modified Release Orally Administered Amino Acid Formulations.”
Market Stats
On Wednesday, RLFTF stock fell 1.70% to $0.0525 with 3.39 million shares, compared to its average volume of 1.74 million shares. The stock moved within a range of $0.0500 – 0.0540 after opening trading at $0.0540.
Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)
The allowed claims involve particular PKU GOLIKE(R) formulations in APR’s product line, which is aimed at improving dietary management of patients living with phenylketonuria (PKU). The PKU GOLIKE(R) family of products, consist of phenylalanine-free food for special medical purposes (FSMP), which includes amino acid granules engineered with APR’s Physiomimic Technology(TM), a modified-release amino acid technology. It ensures prolonged physiological absorption of the amino acids, while also masking their unpleasant taste, odor and aftertaste.
The USPTO issues a patent Notice of Allowance after deciding if a patent should be granted after completing any outstanding administrative requirements. The patent resulting from this application will have an expiration date of no earlier than September 27, 2036.
After being issued, the patent will supplement APR’s PKU GOLIKE(R) intellectual property portfolio, which currently includes U.S. Patent No. 10,500,180, which also expires no earlier than September 27, 2036.
Key Quote
“The receipt of this Notice of Allowance from the USPTO for PKU GOLIKE(R), powered by our proprietary, Physiomimic(TM) Technology, is another important milestone that helps strengthen our intellectual property position, which we will continue to build upon going forward. As we focus on increasing sales in the U.K. and Europe, we will continue our efforts in preparing for a potential U.S. launch,” stated Paolo Galfetti, Chief Executive Officer of APR and President of Relief Europe. “
Traders Corner
RLFTF stock is trading below the 20-Day and 50-Day Moving averages of $0.0609 and $0.0669 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.1118.
